BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 37787999)

  • 21. Development of GPC2-directed chimeric antigen receptors using mRNA for pediatric brain tumors.
    Foster JB; Griffin C; Rokita JL; Stern A; Brimley C; Rathi K; Lane MV; Buongervino SN; Smith T; Madsen PJ; Martinez D; Delaidelli A; Sorensen PH; Wechsler-Reya RJ; Karikó K; Storm PB; Barrett DM; Resnick AC; Maris JM; Bosse KR
    J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36167467
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chimeric Antigen Receptor-modified T Cells Repressed Solid Tumors and Their Relapse in an Established Patient-derived Colon Carcinoma Xenograft Model.
    Teng R; Zhao J; Zhao Y; Gao J; Li H; Zhou S; Wang Y; Sun Q; Lin Z; Yang W; Yin M; Wen J; Deng H
    J Immunother; 2019; 42(2):33-42. PubMed ID: 30586347
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Improved Killing of Ovarian Cancer Stem Cells by Combining a Novel Chimeric Antigen Receptor-Based Immunotherapy and Chemotherapy.
    Klapdor R; Wang S; Hacker U; Büning H; Morgan M; Dörk T; Hillemanns P; Schambach A
    Hum Gene Ther; 2017 Oct; 28(10):886-896. PubMed ID: 28836469
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chimeric antigen receptor T cells to target CD79b in B-cell lymphomas.
    Chu F; Cao J; Liu J; Yang H; Davis TJ; Kuang SQ; Cheng X; Zhang Z; Karri S; Vien LT; Bover L; Sun R; Vega F; Green M; Davis RE; Neelapu SS
    J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 38007239
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Blocking NOTCH pathway can enhance the effect of EGFR inhibitor through targeting CD133+ endometrial cancer cells.
    Shang C; Lang B; Meng LR
    Cancer Biol Ther; 2018 Feb; 19(2):113-119. PubMed ID: 27791463
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pyrvinium Targets CD133 in Human Glioblastoma Brain Tumor-Initiating Cells.
    Venugopal C; Hallett R; Vora P; Manoranjan B; Mahendram S; Qazi MA; McFarlane N; Subapanditha M; Nolte SM; Singh M; Bakhshinyan D; Garg N; Vijayakumar T; Lach B; Provias JP; Reddy K; Murty NK; Doble BW; Bhatia M; Hassell JA; Singh SK
    Clin Cancer Res; 2015 Dec; 21(23):5324-37. PubMed ID: 26152745
    [TBL] [Abstract][Full Text] [Related]  

  • 27. BRD4 inhibition boosts the therapeutic effects of epidermal growth factor receptor-targeted chimeric antigen receptor T cells in glioblastoma.
    Xia L; Liu JY; Zheng ZZ; Chen YJ; Ding JC; Hu YH; Hu GS; Xia NS; Liu W
    Mol Ther; 2021 Oct; 29(10):3011-3026. PubMed ID: 34058385
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeted delivery of a PD-1-blocking scFv by CD133-specific CAR-T cells using nonviral Sleeping Beauty transposition shows enhanced antitumour efficacy for advanced hepatocellular carcinoma.
    Yang C; You J; Pan Q; Tang Y; Cai L; Huang Y; Gu J; Wang Y; Yang X; Du Y; Ouyang D; Chen H; Zhong H; Li Y; Yang J; Han Y; Sun F; Chen Y; Wang Q; Weng D; Liu Z; Xiang T; Xia J
    BMC Med; 2023 Aug; 21(1):327. PubMed ID: 37635247
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting brain lesions of non-small cell lung cancer by enhancing CCL2-mediated CAR-T cell migration.
    Li H; Harrison EB; Li H; Hirabayashi K; Chen J; Li QX; Gunn J; Weiss J; Savoldo B; Parker JS; Pecot CV; Dotti G; Du H
    Nat Commun; 2022 Apr; 13(1):2154. PubMed ID: 35443752
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CAIX-specific CAR-T Cells and Sunitinib Show Synergistic Effects Against Metastatic Renal Cancer Models.
    Li H; Ding J; Lu M; Liu H; Miao Y; Li L; Wang G; Zheng J; Pei D; Zhang Q
    J Immunother; 2020 Jan; 43(1):16-28. PubMed ID: 31574023
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Modulation of invasive properties of CD133+ glioblastoma stem cells: a role for MT1-MMP in bioactive lysophospholipid signaling.
    Annabi B; Lachambre MP; Plouffe K; Sartelet H; Béliveau R
    Mol Carcinog; 2009 Oct; 48(10):910-9. PubMed ID: 19326372
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chimeric antigen receptor containing ICOS signaling domain mediates specific and efficient antitumor effect of T cells against EGFRvIII expressing glioma.
    Shen CJ; Yang YX; Han EQ; Cao N; Wang YF; Wang Y; Zhao YY; Zhao LM; Cui J; Gupta P; Wong AJ; Han SY
    J Hematol Oncol; 2013 May; 6():33. PubMed ID: 23656794
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Minnelide effectively eliminates CD133(+) side population in pancreatic cancer.
    Nomura A; McGinn O; Dudeja V; Sangwan V; Saluja AK; Banerjee S
    Mol Cancer; 2015 Nov; 14():200. PubMed ID: 26597727
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cell-surface antigen profiling of pediatric brain tumors: B7-H3 is consistently expressed and can be targeted via local or systemic CAR T-cell delivery.
    Haydar D; Houke H; Chiang J; Yi Z; Odé Z; Caldwell K; Zhu X; Mercer KS; Stripay JL; Shaw TI; Vogel P; DeRenzo C; Baker SJ; Roussel MF; Gottschalk S; Krenciute G
    Neuro Oncol; 2021 Jun; 23(6):999-1011. PubMed ID: 33320196
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting CD133 in the enhancement of chemosensitivity in oral squamous cell carcinoma-derived side population cancer stem cells.
    Yu CC; Hu FW; Yu CH; Chou MY
    Head Neck; 2016 Apr; 38 Suppl 1():E231-8. PubMed ID: 25545959
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Multispecific Targeting with Synthetic Ankyrin Repeat Motif Chimeric Antigen Receptors.
    Balakrishnan A; Rajan A; Salter AI; Kosasih PL; Wu Q; Voutsinas J; Jensen MC; Plückthun A; Riddell SR
    Clin Cancer Res; 2019 Dec; 25(24):7506-7516. PubMed ID: 31548346
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment.
    Bertolini G; Roz L; Perego P; Tortoreto M; Fontanella E; Gatti L; Pratesi G; Fabbri A; Andriani F; Tinelli S; Roz E; Caserini R; Lo Vullo S; Camerini T; Mariani L; Delia D; Calabrò E; Pastorino U; Sozzi G
    Proc Natl Acad Sci U S A; 2009 Sep; 106(38):16281-6. PubMed ID: 19805294
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New T-Cell Therapies for Brain Metastasis, CD133 in the Driver's Seat.
    Sloan AR; Thapliyal M; Lathia JD
    Clin Cancer Res; 2024 Feb; 30(3):477-479. PubMed ID: 38038689
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Exploitation of CD133 for the Targeted Imaging of Lethal Prostate Cancer.
    Glumac PM; Gallant JP; Shapovalova M; Li Y; Murugan P; Gupta S; Coleman IM; Nelson PS; Dehm SM; LeBeau AM
    Clin Cancer Res; 2020 Mar; 26(5):1054-1064. PubMed ID: 31732520
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Selective Targeting of CD133-Expressing Glioblastoma Stem Cells Using Lentiviral Vectors.
    Bayin NS; Placantonakis DG
    Methods Mol Biol; 2018; 1741():91-101. PubMed ID: 29392693
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.